Once-weekly dose of 8400 IU vitamin D3 compared with placebo

Effects on neuromuscular function and tolerability in older adults with vitamin D insufficiency

Paul Lips, Neil Binkley, Michael Pfeifer, Robert Recker, Suvajit Samanta, Dosinda A. Cohn, Julie Chandler, Elizabeth Rosenberg, Dimitris A. Papanicolaou

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

Background: Vitamin D insufficiency, which is prevalent in older individuals, is associated with bone and muscle weakness and falls. Objective: We examined the effects of a weekly dose of 8400 IU vitamin D3 on postural stability, muscle strength, and safety. Design: In this double-blind trial, subjects aged ≥70 y with serum 25-hydroxyvitamin D [25(OH)D] concentrations ≤20 but ≥6 ng/mL were randomly assigned to receive a weekly dose of 8400 IU vitamin D3 (n = 114) or a placebo (n = 112). Mediolateral body sway with eyes open (assessed with the AccuSwayPLUS platform; Advanced Medical Technology Inc, Watertown, MA) was the primary endpoint. Secondary endpoints included the short physical performance battery (SPPB) and serum 25(OH)D concentrations. An analysis of covariance model was used for treatment comparisons. Safety and tolerability were monitored. Results: Serum 25(OH)D concentrations rose significantly (from 13.9 to 26.2 ng/mL, P <0.001) in patients treated with 8400 IU vitamin D3 but not in patients treated with the placebo. After 16 wk, neither mediolateral sway nor SPPB differed significantly between treatment groups. However, in the post hoc analysis of patients subgrouped by baseline sway (≥0.46 compared with 3 significantly reduced sway compared with treatment with placebo (P = 0.047) in patients with elevated baseline sway but not in patients with normal baseline sway. Adverse experiences and incidences of hypercalcemia, hypercalciuria, and elevated creatinine were similar with both treatments. In patients treated with 8400 IU vitamin D3, but not in placebotreated patients, parathyroid hormone decreased significantly. Conclusions: Weekly treatment with 8400 IU vitamin D3 raised 25(OH)D concentrations in elderly, vitamin D-insufficient individuals. Treatment with 8400 IU vitamin D3 did not reduce mediolateral sway significantly compared with treatment with placebo in this population, although in post hoc analysis, treatment with 8400 IU vitamin D 3 reduced sway in the subgroup of patients who had elevated sway at baseline. Weekly treatment with 8400 IU vitamin D3 was well tolerated. This trial was registered at clinicaltrials.gov as NCT00242476.

Original languageEnglish
Pages (from-to)985-991
Number of pages7
JournalAmerican Journal of Clinical Nutrition
Volume91
Issue number4
DOIs
StatePublished - Apr 1 2010

Fingerprint

Placebo Effect
Cholecalciferol
Vitamin D
Placebos
Therapeutics
Serum
Safety
Hypercalciuria
Muscle Weakness
Hypercalcemia
Muscle Strength
Parathyroid Hormone
Creatinine
Technology
Bone and Bones

All Science Journal Classification (ASJC) codes

  • Medicine (miscellaneous)
  • Nutrition and Dietetics
  • Medicine(all)

Cite this

Once-weekly dose of 8400 IU vitamin D3 compared with placebo : Effects on neuromuscular function and tolerability in older adults with vitamin D insufficiency. / Lips, Paul; Binkley, Neil; Pfeifer, Michael; Recker, Robert; Samanta, Suvajit; Cohn, Dosinda A.; Chandler, Julie; Rosenberg, Elizabeth; Papanicolaou, Dimitris A.

In: American Journal of Clinical Nutrition, Vol. 91, No. 4, 01.04.2010, p. 985-991.

Research output: Contribution to journalArticle

Lips, Paul ; Binkley, Neil ; Pfeifer, Michael ; Recker, Robert ; Samanta, Suvajit ; Cohn, Dosinda A. ; Chandler, Julie ; Rosenberg, Elizabeth ; Papanicolaou, Dimitris A. / Once-weekly dose of 8400 IU vitamin D3 compared with placebo : Effects on neuromuscular function and tolerability in older adults with vitamin D insufficiency. In: American Journal of Clinical Nutrition. 2010 ; Vol. 91, No. 4. pp. 985-991.
@article{5807ae5e56d14adcb71f93d1538f3dec,
title = "Once-weekly dose of 8400 IU vitamin D3 compared with placebo: Effects on neuromuscular function and tolerability in older adults with vitamin D insufficiency",
abstract = "Background: Vitamin D insufficiency, which is prevalent in older individuals, is associated with bone and muscle weakness and falls. Objective: We examined the effects of a weekly dose of 8400 IU vitamin D3 on postural stability, muscle strength, and safety. Design: In this double-blind trial, subjects aged ≥70 y with serum 25-hydroxyvitamin D [25(OH)D] concentrations ≤20 but ≥6 ng/mL were randomly assigned to receive a weekly dose of 8400 IU vitamin D3 (n = 114) or a placebo (n = 112). Mediolateral body sway with eyes open (assessed with the AccuSwayPLUS platform; Advanced Medical Technology Inc, Watertown, MA) was the primary endpoint. Secondary endpoints included the short physical performance battery (SPPB) and serum 25(OH)D concentrations. An analysis of covariance model was used for treatment comparisons. Safety and tolerability were monitored. Results: Serum 25(OH)D concentrations rose significantly (from 13.9 to 26.2 ng/mL, P <0.001) in patients treated with 8400 IU vitamin D3 but not in patients treated with the placebo. After 16 wk, neither mediolateral sway nor SPPB differed significantly between treatment groups. However, in the post hoc analysis of patients subgrouped by baseline sway (≥0.46 compared with 3 significantly reduced sway compared with treatment with placebo (P = 0.047) in patients with elevated baseline sway but not in patients with normal baseline sway. Adverse experiences and incidences of hypercalcemia, hypercalciuria, and elevated creatinine were similar with both treatments. In patients treated with 8400 IU vitamin D3, but not in placebotreated patients, parathyroid hormone decreased significantly. Conclusions: Weekly treatment with 8400 IU vitamin D3 raised 25(OH)D concentrations in elderly, vitamin D-insufficient individuals. Treatment with 8400 IU vitamin D3 did not reduce mediolateral sway significantly compared with treatment with placebo in this population, although in post hoc analysis, treatment with 8400 IU vitamin D 3 reduced sway in the subgroup of patients who had elevated sway at baseline. Weekly treatment with 8400 IU vitamin D3 was well tolerated. This trial was registered at clinicaltrials.gov as NCT00242476.",
author = "Paul Lips and Neil Binkley and Michael Pfeifer and Robert Recker and Suvajit Samanta and Cohn, {Dosinda A.} and Julie Chandler and Elizabeth Rosenberg and Papanicolaou, {Dimitris A.}",
year = "2010",
month = "4",
day = "1",
doi = "10.3945/ajcn.2009.28113",
language = "English",
volume = "91",
pages = "985--991",
journal = "American Journal of Clinical Nutrition",
issn = "0002-9165",
publisher = "American Society for Nutrition",
number = "4",

}

TY - JOUR

T1 - Once-weekly dose of 8400 IU vitamin D3 compared with placebo

T2 - Effects on neuromuscular function and tolerability in older adults with vitamin D insufficiency

AU - Lips, Paul

AU - Binkley, Neil

AU - Pfeifer, Michael

AU - Recker, Robert

AU - Samanta, Suvajit

AU - Cohn, Dosinda A.

AU - Chandler, Julie

AU - Rosenberg, Elizabeth

AU - Papanicolaou, Dimitris A.

PY - 2010/4/1

Y1 - 2010/4/1

N2 - Background: Vitamin D insufficiency, which is prevalent in older individuals, is associated with bone and muscle weakness and falls. Objective: We examined the effects of a weekly dose of 8400 IU vitamin D3 on postural stability, muscle strength, and safety. Design: In this double-blind trial, subjects aged ≥70 y with serum 25-hydroxyvitamin D [25(OH)D] concentrations ≤20 but ≥6 ng/mL were randomly assigned to receive a weekly dose of 8400 IU vitamin D3 (n = 114) or a placebo (n = 112). Mediolateral body sway with eyes open (assessed with the AccuSwayPLUS platform; Advanced Medical Technology Inc, Watertown, MA) was the primary endpoint. Secondary endpoints included the short physical performance battery (SPPB) and serum 25(OH)D concentrations. An analysis of covariance model was used for treatment comparisons. Safety and tolerability were monitored. Results: Serum 25(OH)D concentrations rose significantly (from 13.9 to 26.2 ng/mL, P <0.001) in patients treated with 8400 IU vitamin D3 but not in patients treated with the placebo. After 16 wk, neither mediolateral sway nor SPPB differed significantly between treatment groups. However, in the post hoc analysis of patients subgrouped by baseline sway (≥0.46 compared with 3 significantly reduced sway compared with treatment with placebo (P = 0.047) in patients with elevated baseline sway but not in patients with normal baseline sway. Adverse experiences and incidences of hypercalcemia, hypercalciuria, and elevated creatinine were similar with both treatments. In patients treated with 8400 IU vitamin D3, but not in placebotreated patients, parathyroid hormone decreased significantly. Conclusions: Weekly treatment with 8400 IU vitamin D3 raised 25(OH)D concentrations in elderly, vitamin D-insufficient individuals. Treatment with 8400 IU vitamin D3 did not reduce mediolateral sway significantly compared with treatment with placebo in this population, although in post hoc analysis, treatment with 8400 IU vitamin D 3 reduced sway in the subgroup of patients who had elevated sway at baseline. Weekly treatment with 8400 IU vitamin D3 was well tolerated. This trial was registered at clinicaltrials.gov as NCT00242476.

AB - Background: Vitamin D insufficiency, which is prevalent in older individuals, is associated with bone and muscle weakness and falls. Objective: We examined the effects of a weekly dose of 8400 IU vitamin D3 on postural stability, muscle strength, and safety. Design: In this double-blind trial, subjects aged ≥70 y with serum 25-hydroxyvitamin D [25(OH)D] concentrations ≤20 but ≥6 ng/mL were randomly assigned to receive a weekly dose of 8400 IU vitamin D3 (n = 114) or a placebo (n = 112). Mediolateral body sway with eyes open (assessed with the AccuSwayPLUS platform; Advanced Medical Technology Inc, Watertown, MA) was the primary endpoint. Secondary endpoints included the short physical performance battery (SPPB) and serum 25(OH)D concentrations. An analysis of covariance model was used for treatment comparisons. Safety and tolerability were monitored. Results: Serum 25(OH)D concentrations rose significantly (from 13.9 to 26.2 ng/mL, P <0.001) in patients treated with 8400 IU vitamin D3 but not in patients treated with the placebo. After 16 wk, neither mediolateral sway nor SPPB differed significantly between treatment groups. However, in the post hoc analysis of patients subgrouped by baseline sway (≥0.46 compared with 3 significantly reduced sway compared with treatment with placebo (P = 0.047) in patients with elevated baseline sway but not in patients with normal baseline sway. Adverse experiences and incidences of hypercalcemia, hypercalciuria, and elevated creatinine were similar with both treatments. In patients treated with 8400 IU vitamin D3, but not in placebotreated patients, parathyroid hormone decreased significantly. Conclusions: Weekly treatment with 8400 IU vitamin D3 raised 25(OH)D concentrations in elderly, vitamin D-insufficient individuals. Treatment with 8400 IU vitamin D3 did not reduce mediolateral sway significantly compared with treatment with placebo in this population, although in post hoc analysis, treatment with 8400 IU vitamin D 3 reduced sway in the subgroup of patients who had elevated sway at baseline. Weekly treatment with 8400 IU vitamin D3 was well tolerated. This trial was registered at clinicaltrials.gov as NCT00242476.

UR - http://www.scopus.com/inward/record.url?scp=77950488834&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950488834&partnerID=8YFLogxK

U2 - 10.3945/ajcn.2009.28113

DO - 10.3945/ajcn.2009.28113

M3 - Article

VL - 91

SP - 985

EP - 991

JO - American Journal of Clinical Nutrition

JF - American Journal of Clinical Nutrition

SN - 0002-9165

IS - 4

ER -